Crossmark

The benefit of macrolide therapy in patients with pneumococcal pneumonia is only present in patients with bacteremia

Crossref DOI link: https://doi.org/10.1016/j.pulmoe.2022.08.003

Published Online: 2025-03-10

Published Print: 2023-05-30

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Gonçalves-Pereira, J. https://orcid.org/0000-0002-7538-3777
Costa, L.

Silva, I.

Simões, A. https://orcid.org/0000-0001-6714-8585
Froes, F.

Mergulhão, P.

Varela Ramos, P.

Leal, D.

Alves, R.

Custódio, M.

Gomes, A.
Funding

Funding for this research was provided by:

Merck (60150)

Merck Sharp and Dohme
License Information

Version of Record valid from 2023-05-30
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=tpul20

Publication History

Received: 2022-07-25

Accepted: 2022-08-05

Published: 2025-03-10